NIVO-ALCL - Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma

Project Details

Short titleNIVO-ALCL - Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma
StatusActive
Effective start/end date1/09/19 → 31/08/27

Funding

  • CHILDREN'S CANCER AND LEUKAEMIA GROUP
  • Institut De Cancerologie Gustave Roussy